This would be in line with macrophage-dependent ADCP as reported in the initial clinical trial of combination treatment with murine CD24 and CD21 mAbs of B-cell lymphoma patients [47,48]. Here, CR2 is linked to B-cell non-Hodgkin lymphoma.